Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06416683
Status:
COMPLETED
Last Update Posted:
2024-05-16
First Post:
2024-05-11
Brief Title:
Atezolizumab and Bevacizumab Combination Recommended in a Multidisciplinary Consultation Meeting in Caen for Hepatocellular Carcinoma ABCHCaen
Sponsor:
University Hospital Caen
Organization:
University Hospital Caen
Study Overview
Official Title:
Study of the Atezolizumab and Bevacizumab Combination Recommended in a Multidisciplinary Consultation Meeting in Caen for Hepatocellular Carcinoma
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ABCHCaen
Brief Summary:
In France primary liver cancers PLC is the fourth leading cause of cancer-related death in men and the seventh in women The number of new cases per year is predicted to increase by 265 between 2020 and 2040 Hepatocellular carcinoma HCC account for 75 to 85 of PLC It occurs mostly on cirrhotic livers Diagnosis remains late in almost half of the patients so that a palliatif treatment is frequent In advanced cases sorafenib has been so far the first line systemic therapy since 2008 In 2020 a phase 3 study has demonstrated a better overall survival in patients treated with bevacizumab associated with atezolizumab as compared to sorafenib 192 months vs 134 months and a better quality of life Noweday immunotherapy is recommended in first line in cases of ECOG 01 unresectable HCC without liver insufficiency However the study included 70 of viral liver diseases while HCC are related to alcohol and steatohepatitis in 50 of cases in France Moreover patients with high risk of oesophageal variceal bleeding were excluded Recent real life data published worldwide confirm the bitherapy efficacy and good tolerability By contrast french data are scarces with a single serie of 43 patients in which median overall survival was estimated to 12 months Our main aim is to determine the overall survival of HCC patients treated with atezolizumab and bevacizumab in Caen from april 2021
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None